Ovarian Cancer Treatments: Role of 1st Line Bevacizumab, Maintenance Olaparib and Single Agent Immune Checkpoint Inhibitors in Advanced Setting

0 views
August 20, 2019
Comments 0
Login to view comments. Click here to Login